Aptose Biosciences reported a net loss of $7.6 million in Q1 2026, up from $5.5 million a year earlier, driven by increased research and development expenses for its AML drug tuspetinib. The company's TUSCANY trial combining tuspetinib with venetoclax and azacitidine shows promising safety and efficacy data, with updated results to be presented at the EHA 2026 Congress. Aptose's planned acquisition by Hanmi Pharmaceutical is delayed due to pending Korean regulatory approvals but is still expected to close in May 2026. The company is also returning license rights for another drug, luxeptinib, to CGI and is implementing cost reductions to extend its cash runway, currently at $4.1 million.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
China's $1.39 trillion program to clean up hidden local government debt is succeeding in reducing off-book borrowing but is causing austerity-like effects. Local governments, key drivers of infrastructure spending and economic growth, are cutting bac...
In Q2 2026, top contributors to growth included Taiwan Semiconductor Manufacturing, Alphabet, United Rentals, Apple, and Visa. Alphabet’s Google Search and Cloud segments showed robust revenue growth of 19% and 63%, respectively, boosting operating i...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
BlackRock reported strong Q2 results with net inflows of $192 billion, pushing assets under management (AUM) to a record $15.3 trillion. The firm's ETF business showed strong momentum, supported by new product launches and inclusion in Trump accounts...
